Daiichi Sankyo
Also known as: Daichii Sankyo | Daiichi Sankyo | DAIICHI SANKYO | Daiichi Sankyo Brasil Farmacêutica LTDA | Daiichi Sankyo Co., Ltd. | Daiichi Sankyo Company, Limited | Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo | Daiichi Sankyo Development | Daiichi Sankyo Europe, GmbH | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Daiichi Sankyo Inc. | Daiichi Sankyo, Inc | Daiichi Sankyo, Inc. | DAIICHI SANKYO INC | Daiichi Sankyo Korea Co., Ltd. | Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company | Daiichi Sankyo Taiwan Ltd. | Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company | Daiichi Sankyo UK Ltd. | Luitpold Pharmaceuticals | R&D Division, Daiichi Sankyo Co., Ltd. | Sankyo Shanghai Pharmaceuticals
Highest phase reached
Phase 4
First clinical trial
Feb 1, 1994First marketed drug
Jan 11, 2000First NDA
Jan 8, 2015Last known activity
Feb 28, 2026
Timeline
1940s
- Jun 1, 1947
Daiichi Sankyo— Founded
2000s
- May 26, 2000
colesevelam— NDA Secondary Org
- Jan 1, 2005
Daiichi— Acquired
- Jan 1, 2005
Sankyo— Acquired
- Mar 31, 2006
Zepharma Inc.— Acquired
- May 21, 2008
U3 Pharma GmbH— Acquired
2010s
- Jan 6, 2010
PharmaForce, Inc— Acquired
- Dec 13, 2010
Roxro Pharma— Acquired
- Apr 4, 2011
Plexxikon— Acquired - Sep 28, 2014
Ambit Biosciences— Acquired
- Apr 1, 2015
Asubio— Acquired
- Aug 2, 2019
pexidartinib— Marketing Organization
- Dec 20, 2019
fam-trastuzumab deruxtecan-nxki— NDA Organization
Drugs by trial phase (241 distinct, 605 trials)
Phase 4 (30 own, 7 via acquisition)
Phase 3 (57 own, 17 via acquisition)
Phase 2 (47 own, 11 via acquisition)
Phase 1 (59 own, 10 via acquisition)
Other trials (3 own, 0 via acquisition)
Indications
Studied for
- Acute Coronary Syndrome
- Adenocarcinoma
- Albuminuria
- Anemia
- Anemia, Iron-Deficiency
- Anemia, Sickle Cell
- Aortic Valve Stenosis
- Arteriosclerosis
- Arthritis
- Arthritis, Rheumatoid
- Asthma
- Atherosclerosis
- Atrial Fibrillation
- Bile Duct Neoplasms
- Biliary Tract Neoplasms
- Body Weight
- Bone Diseases
- Bone Marrow Diseases
- Bone Neoplasms
- Brain Neoplasms
- Breast Neoplasms
- Cachexia
- Calciphylaxis
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Cardiomyopathies
- Cardiovascular Diseases
- Carotid Artery Diseases
- Central Nervous System Neoplasms
- Cerebral Infarction
- Cholangiocarcinoma
- Chronic Disease
- Colorectal Neoplasms
- Coronary Artery Disease
- Coronary Disease
- Coronary Restenosis
- Coronary Stenosis
- Coronavirus Infections
- Deficiency Diseases
- Dermatitis
- Dermatitis, Atopic
- Desmoplastic Small Round Cell Tumor
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Diabetic Neuropathies
- Digestive System Neoplasms
- Dyslipidemias
- Eczema
- Embolism
- Embolism and Thrombosis
- Endometrial Neoplasms
- Esophageal Neoplasms
- Essential Hypertension
- Fallopian Tube Neoplasms
- Fatty Liver
- Fibromyalgia
- Gallbladder Neoplasms
- Gastrointestinal Neoplasms
- Gastrointestinal Stromal Tumors
- Giant Cell Tumor of Tendon Sheath
- Giant Cell Tumors
- Glioma
- Glomerulonephritis
- Glucose Intolerance
- Head and Neck Neoplasms
- Heart Diseases
- Heart Failure
- Heart Failure, Systolic
- Hemorrhage
- Hip Fractures
- Hypercholesterolemia
- Hyperlipidemia, Familial Combined
- Hyperlipidemias
- Hyperlipoproteinemias
- Hyperlipoproteinemia Type II
- Hyperphosphatemia
- Hypertension
- Hypophosphatemia
- Infarction
- Infections
- Inflammatory Bowel Diseases
- Influenza, Human
- Insulin Resistance
- Intestinal Diseases
- Ischemia
- Kidney Diseases
- Kidney Failure, Chronic
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia-Lymphoma, Adult T-Cell
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, T-Cell
Marketed drugs (69)
Subsidiaries (9 direct, 11 total across the full acquisition tree)
Recent trials (50)
- NCT06099639Study directorN/A—
- NCT06279728OfficialN/A—
- NCT03746912Lead sponsorN/A—
- NCT06099639Lead sponsorN/A—
- NCT06279728Lead sponsorN/A—
- NCT07303387CollaboratorPhase 2Feb 28, 2026
- NCT07286149CollaboratorPhase 1/Phase 2Feb 9, 2026
- NCT07268625Lead sponsorPhase 1Jan 5, 2026
- NCT07227597CollaboratorPhase 1/Phase 2Dec 12, 2025
- NCT07244341Lead sponsorPhase 1Nov 20, 2025
- NCT07159126Lead sponsorPhase 1Nov 9, 2025
- NCT07189403Lead sponsorPhase 1Nov 4, 2025
- NCT07291037CollaboratorPhase 3Oct 31, 2025
- NCT07022483Lead sponsorPhase 3Oct 31, 2025
- NCT07235189Lead sponsorPhase 1Oct 28, 2025
Details
- Founded
- Shirley, NY, US Jun 1, 1947
- First NDA
- Jan 8, 2015
- Last known activity
- Feb 28, 2026
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
- Accelerated approval
Notes
--- Pre-folding founded info: 2005-01-01 Tokyo JP http://www.daiichisankyo.com/about_us/who_we_are/history/index.html --- --- Notes from Luitpold Pharmaceuticals: https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006857.html ---